Gedeon Richter Releases Patient Information for Norcolut Medication

Gedeon Richter Plc. has released comprehensive patient information for its product Norcolut, containing the active substance norethisterone. The medication, available as 5 mg tablets, is indicated for adult women aged 18 and above.

Norcolut belongs to the progestogen class of drugs, which are substances similar to the natural female sex hormone progesterone. Norethisterone works by suppressing the secretion of gonadotropic hormones from the pituitary gland, thereby inhibiting follicle maturation and ovulation. It also aids in transforming the uterine lining.

The drug is indicated for conditions such as premenstrual syndrome, mastodynia (breast pain and tenderness), menstrual cycle irregularities, dysfunctional uterine bleeding, endometrial hyperplasia, endometriosis, and adenomyosis. A physician evaluates the suitability for each patient.

The patient leaflet emphasizes several contraindications and precautions. These include hypersensitivity to norethisterone or other components, hormone-dependent cancers, history of blood clots (e.g., deep vein thrombosis, pulmonary embolism), certain cardiovascular conditions, and severe liver disease. Patients are advised to cease medication immediately upon noticing potential signs of thromboembolism, such as leg pain, shortness of breath, or sudden visual disturbances.